John Flavin

Excited to have led the closing panel entitled "Bridging Science and Investment" in San Diego, CA. Joined by Dr. Sanjeev Thohan (Cogentis Therapeutics, Inc./Phoenix Molecular Designs) and Dr. Yuhua Ji (Grace Science, LLC ), we explored the intersection of scientific innovation and investment strategies. Key topics of this thought-provoking panel included: - Strategic investment approaches in the evolving biotech landscape - The critical role of venture capital in accelerating drug discovery - Innovative funding models for cutting-edge pharmaceutical research - The future of biotechnologies and the investment opportunities they present Thank you to the panelists for sharing their invaluable insights. Our discussion underscored the vital role of strategic investments in driving innovation and shaping the future of drug discovery and development. Together, we are paving the way for groundbreaking advancements in biotech. #biotechnology #MedicinalChemistry, #strategy #drugdevelopment Proventa International #Bio2024 BIO International Convention #DrugDiscovery #Investment #VentureCapital #Biotech #SanDiego American Association for Precision Medicine (AAPM) WISE World Investors & Entrepreneurs Society Agility Pharmaceuticals Precision BioPharma #ai #news

35

2 Comments

Looking back at the past 30 years, I remember myself doing science about 55-60 hours a week, and then helping venture capitalists and biotech start-ups about 70-80 h/week. Usually unsatisfied, sometimes exhausted, but pleased overall. This overexciting workaholism was somehow interrupted last year. I had less work and a lot of mountaineering, - climbed about 5.5 Chomolungma attitudes during the year. It feels like I have reached the stage at which it is a time to start sharing experiences and understanding of the universe. This week, I started to share by publishing an analytic report at SeekigAlpha about TG Therapeutics. This small biotech company has developed a third-to-market anti-CD20 mAb for the treatment of multiple sclerosis (MS). Along with the company, this report briefly touches upon current treatments for MS, the competitive landscape of therapeutics, and the uncertainties surrounding the development of new BTK inhibitors. https://lnkd.in/drAFx9vt

10

This will be a fascinating SynBioBeta talk - on how the combined tools of synthetic biology allowed Creyon Bio to build a successful drug in a few months 😳

13

🚀 Attention Investors and Healthcare Leaders! 🚀 R3i are thrilled to celebrate StratifiCare™ Pte. Ltd.'s CEO, Anthony Chua, who just landed in Dallas, Texas, to accelerate the progress of two revolutionary personalized medicine diagnostics: 🌟 Stratifiden - The world's first severe dengue prognostic that reduces unnecessary hospitalization by 67%, easing the emotional and financial burden on families. 🌟 Stratifirey - The world's first liver cancer diagnostic that predicts patient response to Y90 RE treatment, allowing clinicians to make informed decisions and reduce the agonizing 3 to 6-month wait for results. StratifiCare's journey is a testament to perseverance and innovation. To develop these groundbreaking products, it secured $35M in non-dilutive capital and less than $1M in venture capital. Anthony Chua's unwavering determination teaches us the power of persistence and the impact of every step forward. A special thank you to David Jacobson for welcoming StratifiCare™ Pte. Ltd. into our Texas triangle and the SMU Cox School of Business community. 💡 Investors and hospital administrators, this is your chance to be part of a transformative journey in personalized medicine. Reach out and learn how you can support and benefit from these pioneering advancements. Together let's accelerate impact 💡 NUS Overseas Colleges National University of Singapore Singapore Economic Development Board (EDB) #HealthcareInnovation #PersonalizedMedicine #DengueDiagnostic #LiverCancerDiagnostic #StratifiCare #InvestmentOpportunities #HealthcareLeaders #MedicalBreakthroughs #Valuebasedcare Enterprise Singapore

25

In Episode 3 of the "Brain Cancer Science Talk" series on #MissionGBM, we chat with John de Groot, MD (Division Chief of Neuro-Oncology, UCSF) about immunotherapies, the need for combination protocols, Focused Ultrasound, and necessary improvements to clinical trial design and Regulatory framework to advance the development of treatment options for #braincancer patients. #FUS #ImmunoOncology #GBM #Onward #Nof1onBehalfofAll

34

Some great advice in this interview — featuring Jeffry Weinhuff of Visionary Ventures — relevant to all sub-sectors of #medtech. My favorite line is “investment capital is not tuition.” 😂 But the best advice stems from the insight that good exits via IPO or M&A processes with multiple buyers competing for your company require that most medtech companies must prove their value via strong commercial metrics. And doing that takes a lot of time, expertise and money. Plan, hire and raise capital accordingly. At Vensana Capital, our investment process centers on a deep analysis of every aspect of getting a breakthrough medtech innovation to market, no matter what stage of development a company is at today. We like entrepreneurs who believe their innovation can be highly impactful to patients. We love the ones who want to leave no doubt. https://lnkd.in/eDsUqgn6

81

1 Comment

Our founder and CEO Jen Nwankwo, Ph.D. sat with Genetic Engineering & Biotechnology News to discuss our differentiated multimodal data strategy, which integrates computational data, wet lab proxy biological data, and wet lab ground truth biological data to overcome the low data regime problem that has historically limited the application of state-of-the-art foundational models in the pharmaceutical industry.    To advance small and large molecule drug discovery, we employ a multimodal AI platform powered by laboratory automation. Our platform’s name—Input, Transform, Output (ITO)—reflects our company’s comprehensive approach, spanning proprietary data generation, data orchestration, AI, and high throughput laboratory automation in iterative training and testing loops.    To gain access to our ITO platform, click here: https://lnkd.in/ek9dbk3T  Read the full GEN feature: https://lnkd.in/gynQxCjF   

45

How can we design better molecules? In the latest episode of the Climate Capital Podcast, Mitchell Duffy (CEO at Cambrium) and Michael Luciani (Managing Partner at Climate Capital) discuss how the Cambrium team finds answers to this question, leveraging molecular design technology to engineer proteins and revolutionize material creation. Find the links to the episode on Spotify and Apple Podcast in the comments. #MaterialsThatMatter

145

4 Comments

#VentureCapital is flowing again into #biotech, but the slower pace of investments can impact the ways CEOs are being compensated.   CEO & Managing Partner Leslie Loveless offers her perspectives on the topic in this insightful new article in BioSpace.    She explains that pay packages and one’s appetite for risk help determine whether a CEO candidate is right for the job.   “There are a lot of people that are very drawn to the higher-risk, higher-reward scenario that you see in biotech, and if that is what you’re drawn to, great. Go for it,” Loveless said. “But if that is not how you are wired, if that’s not in your DNA, then I would encourage folks to appreciate that about themselves. And don’t go into a negotiation with a biotech wanting them to pay you like they are Big Pharma, because they’re not going to. That’s not how they’re wired.”   We appreciate the coverage, Angela Gabriel!   #lifesciences #executivesearch

28

3 Comments

Fascinating Low Valuation on IPA Therapeutics(NASDAQ:IPA $1.26) On March 29, 2022 IPA paid $20 million euros or approximately $22 million USD for BioStrand AI. The euro was trading(1 euro = 1.10 USD) at this time. Since this acquisition BioStrand AI has announced several significant events/successes including, granting of the HYFT Technology Patent by the European Patent Office(EPO), BioStrand solves the Information Integration Dilemma(IID), BioStrand creates a revolutionary approach to biological sequence retrieval, BioStrand introduces an advanced Foundational AI Model utilizing LLM stacking & HYFT Technology, InterSystems & BioStrand AI Collaborate to Unveil Innovative Integration of Vector Search, BioStrand's AI has been learning from IPA's leading, proprietary Antibody Discovery Database(possibly the best in the World)for the last 24 months, and much more. IPA has been working on antibody research for 40+ years. https://lnkd.in/gJHWdgck https://blog.biostrand.ai Yet, the entire current Market Capitalization of IPA(CRO + BioStrand + Talem) is approximately $35 million USD today. IPA's Contract Research Organization(CRO) has had 3 record revenue quarters in a row, is growing at approx. 20%, and Fiscal 2024 Revenue should be around $20 million USD. They deal with 19 of the top 20 pharmas, and have over 600 partners. One could argue that the CRO is worth between $80-$120 million. FairJourney Biologics(an excellent CRO) was just put up for sale for $1 Billion+. Although FJBio has $45 million in projected EBITA, IPA has better numbers regarding projects, libraries generated, partners, species used, and 1/2 the employees. In other words, better data to train the AI models. Wet lab combined with AI will be critical moving forward. I also believe BioStrand AI is undiscovered by most stock market participants. For Information Purposes Only. Please complete your own due diligence. CFP has a position in IPA. Is a short squeeze possible? Sum of the parts(1 + 1 = 11) IPA (ImmunoPrecise Antibodies)BioStrand (a subsidiary of IPA) InterSystems hashtag #ai hashtag #HYFTTechnology hashtag #drugdiscovery hashtag #LENSai hashtag #antibodies hashtag #LLMS hashtag #NLP hashtag #semantics hashtag #pharma hashtag #healthcare hashtag #biotech hashtag #multimodality

14

8 Comments

I’m excited to share my recent conversation with Joel Beasley | Modern CTO on the Modern CTO Podcast. We discussed my pivot from clinical medicine to the founding of Northpond Ventures, focusing on practical lessons from career transitions and the real-world impact of biotechnology innovations. Here are some of the highlights:  1. How I managed to reshape my career around personal strengths and market needs 2. The importance of support systems in overcoming professional challenges 3. How venture capital can drive scientific innovation into marketable solutions 4. An overview of Northpond Ventures’ strategy in fostering partnerships with leading academic institutions You can listen to the full episode here: https://lnkd.in/eGDzY98h #Biotechnology #Tech #Leadership #CareerChange #VentureCapital #Entrepreneurship

30

1 Comment

This article by the WSJ is critically important for public health officials and HealthTech entrepreneurs to internalize. We need multiple solutions for patients to move towards post GLP-1 usage. These solutions need to be easy to implement, non-disruptive to daily life and focused on caloric restriction , lifestyle change and muscle gain. Too many startups are still focused on GLP-1 prescription and delivery. Not enough people focused on the next stage of the weight management journey. As the Journal states, the benefits of the GLP-1 craze are only going to be successful long term if the transition off of them is successful. Otherwise, we risk unforeseen, long term consequences to a large group of patients stuck on GLP-1's with no healthy way to transition off. https://lnkd.in/dYBd3HaN Meghan FitzGerald James Stearns Dominic Perks John LaMattina Raju Kucherlapati

29

2 Comments

This is exciting! Prolific Machines, Inc. based in Emeryville, California, has raised $55 million in a Series B round led by Ki Tua Fund. The company, founded in 2020 by Deniz Kent, PhD, Max Huisman, and Declan Jones, focuses on using light to optimize cell growth for producing proteins used in food and medicine. Traditional methods of growing cells involve expensive and hard-to-control molecular processes. Prolific Machines believes light offers a cheaper and more precise alternative. Their bioreactors use light to direct cell growth, potentially reducing costs and improving consistency. The new funding will help Prolific Machines commercialize their technology and acquire customers. The company is already engaging with commercial partners and aims to make their bioreactors available for producing high-value bioproducts like nutritional proteins and antibodies. What do you think? https://lnkd.in/dkSbZ_wQ

20

According to the latest Pitchbook data, venture creation in biotech hit its slowest quarterly pace in eight years during 1Q 2024. With just over 60 new biotechs raising their first round of financing, the sector’s company formation activity has slowed 50-60% from its historic peak in 2021. Thank you Bruce Booth for penning your views on why this is a good thing. -Contraction in venture creation IS a healthy dynamic for the sector. -We need to ensure that the best ideas are getting advanced by the sector. -Greater discipline should translate into better returns in the long term for LPs and GPs/ VC #Venturecapital #Startups

25

2 Comments

Turn Biotechnologies, one of our portfolio companies, inked a $300m epigenetic reprogramming deal with Korean pharma giant (news in the comment). Founded in 2018 as a spinout from Stanford University, Turn Bio develops epigenetic reprogramming technology aiming to restore optimal gene expression and promote tissue regeneration by tackling aging effects in the epigenome. To achieve that, the company uses a specific cocktail of mRNA transcription factors. In its exclusive global licensing agreement with Korean pharma giant HanAll Biopharma, Turn Bio’s role is to develop multiple epigenetic reprogramming treatments for age-related eye and ear conditions. Ever since LongeVC investment in Turn Bio back in 2022, I’ve been watching the space of RNA therapeutics with interest. I think one of the most important aspects of Turn Bio is eTurna™ delivery platform, addressing the challenge of delivering RNA-based treatments. Delivery is a pain point in all RNA therapeutics. eTurna™ platform is customizable for different types of cargoes and routes of administration, using ionizable lipids that are safer and clear the body quickly. It reduces immunogenicity and enhances delivery efficiency. As Turn Bio co-founder Vittorio Sebastiano said, the power of the company’s technology is its ability to “rejuvenate cells in virtually any organ in the body.” Recently, Turn Bio also received positive feedback from the FDA during an INTERACT meeting regarding their skin rejuvenation therapy, TRN-001 (link in the comments). This puts the company on track to become the first longevity biotech to take cell rejuvenation therapy to clinic! #mRNA #rejuvenation #longevity #agingresearch Image credit: Longevity.Technology

89

5 Comments

🎙️ Thrilled to share that V. Tyrone Lam, COO of GATC Health, was recently featured on the Innovation Wave Podcast! In this insightful 20’ episode with Bob McGriff and me, Ty delves into how AI-driven predictive analytics can transform our approach to disease treatment, making it more proactive and less risky. He shared compelling insights on the future of healthcare and how predictive tools can lead to earlier interventions and better patient outcomes. A must-listen for anyone interested in the cutting-edge of medical technology and AI! 👉 Check out the episode to learn more about Tyrone's vision and GATC Health's pioneering work in this exciting field. Let's discuss how these innovations are reshaping the landscape of healthcare! #HealthTech #AI #PredictiveAnalytics #Innovation

31

12 Comments

"“The detection of AFib significantly improved over the past two decades, primarily due to advancements in technology, changes in clinical practice and increased awareness,” the authors wrote. “Approximately a third of patients with AFib are asymptomatic, and enhanced detection over time may lead to increased lifetime risk of diagnosed AFib. Another possible reason is the global increase in life expectancy.” Meanwhile, AFib patients faced high lifetime risks of developing heart failure (41%) or experiencing a stroke (21%). The lifetime risk of an AFib patient suffering a myocardial infarction was 12%. “Our findings encourage greater attention to secondary prevention of heart failure after AFib, and in line with a recent report from the National Heart, Lung, and Blood Institute, relevant future initiatives include development of non-anticoagulant pharmacotherapies, effective implementation of weight loss and risk factor modification, and designing successful programs for cardiac rehabilitation. As AFib is a common arrhythmia, a lower incidence of complications may reduce the future economic costs in healthcare.”" MedTech Innovator American Heart Association Heart Rhythm Society American College of Cardiology #epeeps LSI

44

2 Comments